Alfasigma Italia

What Alfasigma Italia does

Alfasigma Italia, operating through its legal entity Alfasigma S.p.A., is an Italian pharmaceutical company that develops, manufactures, and distributes pharmaceutical products and related therapies across multiple therapeutic areas. The company was established on August 1, 2017, through a merger by absorption (fusione per incorporazione) that consolidated three pre-existing Italian pharmaceutical companies: Alfa Wassermann S.p.A., Biofutura Pharma S.p.A., and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Alfasigma succeeded by operation of law to all active and passive legal relationships of the absorbed entities, including marketing authorizations (AIC) for medicinal products, without interruption to ongoing operations.

The company is headquartered at Via Ragazzi del '99, 5, 40133 Bologna, Italy, operating as a privately held joint-stock company (S.p.A.) under Italian law. Its legacy Alfa Wassermann website (alfawassermann.it) was maintained post-merger specifically to complete the administrative transfer of product authorizations from Alfa Wassermann S.p.A. to Alfasigma, indicating an ongoing regulatory consolidation process. The primary Alfasigma corporate website is hosted at it.alfasigma.com. The company maintains a data-protection office reachable at [email protected].

No specific product names, therapeutic area breakdowns, revenue figures, headcount, customer segments, or go-to-market model details are disclosed in the available source data. The business model appears to be a vertically integrated pharmaceutical operation spanning drug development through distribution, inherited from three predecessor entities with established positions in the Italian and potentially broader European pharmaceutical markets.

Name

Alfasigma Italia

Legal name

Alfasigma S.p.A.

Website

https://alfawassermann.it

Company type

Private

Founded year

2017

Operating status

Operating

Short description

Alfasigma Italia is a privately held Italian pharmaceutical company (Alfasigma S.p.A.) that develops, manufactures, and distributes pharmaceutical products and therapies across multiple therapeutic areas, formed in 2017 through the merger of Alfa Wassermann, Biofutura Pharma, and Sigma-Tau Industrie Farmaceutiche Riunite.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical products
• Specialty pharmaceuticals
• Prescription medicines
• Drug manufacturing
• Therapeutic treatments

Headquarters

HQ city

Castel Guelfo Di Bologna

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Alfasigma Italia (Alfasigma S.p.A.) develops, manufactures, and distributes pharmaceutical products and therapies for multiple therapeutic areas, succeeding to the active and passive relationships (including medicinal product marketing authorizations) of Alfa Wassermann S.p.A., Biofutura Pharma S.p.A., and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. following the August 1, 2017 merger. The company operates from its registered office in Bologna, Italy, with products distributed under pharmaceutical regulatory frameworks.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical specialties (specialità medicinali) — legacy Alfa Wassermann portfolio Medicinal specialties for which marketing authorizations (AIC) were previously held by Alfa Wassermann S.p.A. and are being transferred to Alfasigma S.p.A. following the August 1, 2017 merger; distributed to Italian healthcare channels.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights2 records

Direct peers

• Chiesi Farmaceutici: Privately held Italian pharmaceutical manufacturer headquartered in Parma, with both proprietary branded products and a strong hospital/specialty-care distribution footprint across multiple therapeutic areas. Highly comparable as another family-controlled Italian pharma of similar scale and integrated manufacturing-distribution model.
• Dompé farmaceutici S.p.A. Milan-based Italian pharmaceutical company combining proprietary primary-care products with biotech-driven specialty care in ophthalmology and rare diseases. Comparable as an Italian-headquartered integrated pharma with a multi-area portfolio and a private/owner-controlled ownership structure.
• Recordati Industria Chimica e Farmaceutica S.p.A. Italy-founded, Milan-listed pharmaceutical company with a diversified specialty and primary-care portfolio across multiple therapeutic areas plus a strong presence in rare diseases. Comparable because it operates out of Italy with a multi-therapy-area branded-and-specialty model serving similar European prescribers and payors.
• Angelini Pharma: Privately owned Italian pharmaceutical group active across branded prescription, consumer health, and OTC categories in multiple therapeutic areas with European and emerging-market reach. Comparable as another Italian-headquartered, privately controlled pharma combining in-house manufacturing with multi-area distribution.
• Zambon S.p.A. Italian family-controlled pharmaceutical and fine chemicals company with manufacturing in APIs and finished dosage forms across respiratory, pain, and CNS therapeutic areas. Comparable as another Italian privately held integrated pharma operating in similar therapeutic categories and European markets.
• Menarini Group: Florence-based, family-owned Italian pharmaceutical manufacturer with a broad multi-therapeutic-area branded portfolio, significant biologics capability, and a wide European plus emerging-markets distribution network. Comparable as an Italy-rooted, privately held pharma of similar combined manufacturing-and-distribution scope.

Broad incumbents

• STADA Arzneimittel AG: European-centered generics, specialty, and consumer health pharmaceutical group owned by private equity. Comparable as a mid- to large-scale European pharma whose multi-therapy-area generics and specialty portfolio competes for the same hospital and retail demand in Italy and across the EU.
• Teva Pharmaceutical Industries Ltd. Global leader in generic and specialty medicines, with a portfolio spanning multiple therapeutic areas and strong European distribution. Comparable as a large incumbent whose generics and specialty care franchises overlap with Alfasigma's multi-therapy-area offerings in Europe.
• Viatris Inc. Global off-patent pharmaceutical company combining generic and established brands across multiple therapeutic areas with extensive European reach. Comparable as a broad incumbent whose established-brand and generic portfolio overlap with Alfasigma's multi-area pharmaceutical offering in European and other international markets.
• Sandoz Group AG: Spin-off generics and biosimilars arm of Novartis, operating globally across a broad set of off-patent molecules and dosage forms. Comparable because Alfasigma's generic and established-branded pharmaceuticals serve similar off-patent and value-added prescription markets, particularly across European payors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alfasigma Italia